Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage

ConclusionFor patients with MS having breakthrough disease on QW INF β1a, switching to more frequently administered INFβ may be an option. Advantages to using IM INFβ1a for this include no skin reactions and a lower incidence of neutralizing antibodies. Further pragmatic, observational, larger-group studies comparing treatment with Avonex® and higher dosed IM INF β1a, such as the recently FDA-approved IM peginterferon beta-1a, may be indicated.
Source: Neurology and Therapy - Category: Neurology Source Type: research